Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:clinicalTrialPhase |
Phase 3 (paltusotine)
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
rare diseases
endocrine diseases |
| gptkbp:founded |
2008
|
| gptkbp:founder |
Scott Struthers
|
| gptkbp:hasCompany |
true
|
| gptkbp:headquarters_location |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Crinetics Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:lead_product_candidate |
paltusotine
|
| gptkbp:numberOfEmployees |
over 100
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
CRNX
|
| gptkbp:therapeuticArea |
gptkb:Cushing's_disease
acromegaly neuroendocrine tumors |
| gptkbp:website |
https://www.crinetics.com/
|
| gptkbp:bfsParent |
gptkb:Sorrento_Mesa
|
| gptkbp:bfsLayer |
8
|